Merck & Co. Inc. (NYSE:MRK) on Thursday released results from the Phase 3 STRIDE-13 trial evaluating Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) at the European Society of Clinical ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck, known as MSD outside of the United States and Canada, today announced positive results from the Phase 3 STRIDE-13 trial evaluating CAPVAXIVE ® (Pneumococcal ...

HONG KONG, Jun 20, 2025 - (JCN Newswire) - - Pneumonia is a form of acute respiratory infection, that is common in all age groups and can cause mild to life-threatening illness. It is also the single ...

Sanofi SNY and its partner SK bioscience announced that they have expanded their agreement to develop, license and commercialize next-generation pneumococcal conjugate vaccines (PCVs) for treating ...

The Centers for Disease Control and Prevention (CDC) now recommends that American adults over the age of 50 receive the pneumococcal conjugate vaccine, or PCV. The report with the updated ...

EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults “Pneumococcal disease continues to pose a significant risk for adults in Europe, among adults who are 65 or ...

These findings support the proactive administration of an additional pneumococcal vaccine dose at the time of planning cochlear implant surgery for children ≥2 years old. In addition, periodic ...

The National Vaccine Committee has approved the national vaccine security strategy and agreed to push for the inclusion of ...